retatrutide triple agonist obesity trial 🚨 TRIUMPH-1 Phase 3 top-line results, much awaited and just announced ⬇️ 28.3% Weight loss at 80 weeks ⬇️ 30.3% weight loss at 104 weeks among adults with baseline BMI >35 Retatrutide is a triple-agonist (GLP-1

Prioritize foods that fuel, not just fill GLP1s help reduce cravings, but your diet still plays a major role

Tirzepatide best result: 22.5% body weight loss over 72 weeks on the 15mg dose, versus 2.4% for placebo

Medically Supervised Treatment Youll receive expert guidance throughout your journey to ensure safety and effectiveness

Understanding your insurance coverage and out of pocket costs before youre treated should be table stakes in healthcare

He has acted as consultant for Abbvie, Actelion, Aelin Therapeutics, AgomAb, Aligos Therapeutics, Allergan, Alnylam, Astellas, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristoll-Meyers Squibb, CSL Behring, Coherus, Echosens, Dr

Short-acting and long-acting preparations of GLP-1RA have distinct effects on controlling blood sugar (58)